MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates [Yahoo! Finance]
MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates
MoonLake Immunotherapeutics (NASDAQ: MLTX) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $67.00 price target on the stock.
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $82.00 to $73.00. They now have a "buy" rating on the stock.
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its price target raised by analysts at Needham & Company LLC from $62.00 to $66.00. They now have a "buy" rating on the stock.